NVSNovartis PharmaceuticalsSigning up patients
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Chronic Myeloid Leukemia (CML)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 20 (planned)
- Started
- Feb 18, 2025
- Main results expected
- Feb 17, 2029
- Fully finished
- Feb 18, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Rate of BCR::ABL1 (Breakpoint Cluster Region Gene::Abelson proto-oncogene) IS (International Scale) ≤ 1% [MR2 (Molecular Response 2)]
Measured over: Month 12
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06514534 · record last updated 2026-04-21 · checked 2026-11-09 15:47 UTC